期刊
TRENDS IN NEUROSCIENCES
卷 36, 期 9, 页码 543-554出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tins.2013.06.003
关键词
Parkinson's disease; glutamate; serotonin; acetylcholine; GABA; norepinephrine; dopamine; striatum; substantia nigra; basal ganglia
资金
- US Army Medical Research contract [W81XWH-10-1-0640, W81XWH-12-1-0039, W81XWH-09-1-0402, W81XWH-10-1-0691]
- JPB Foundation
- Brain Research Foundation
For several decades, the dopamine precursor levodopa has been the primary therapy for Parkinson's disease (PD). However, not all of the motor and non-motor features of PD can be attributed solely to dopaminergic dysfunction. Recent clinical and preclinical advances provide a basis for the identification of additional innovative therapeutic options to improve the management of the disease. Novel pharmacological strategies must be optimized for PD by: (i) targeting disturbances of the serotonergic, noradrenergic, glutamatergic, GABAergic, and cholinergic systems in addition to the dopaminergic system, and (ii) characterizing alterations in the levels of neurotransmitter receptors and transporters that are associated with the various manifestations of the disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据